Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.
Double Bottom Line Challenge Update: Lumira Ventures gives to five additional initiatives in our communities to support those in need during the COVID-19 crisis.
May 29, 2020
Over the past several weeks, we have seen a number of provinces and states relax restrictions and open up further. Combined with the start of summer, this has caused many to ease on social... Learn More
May 1, 2020
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced its intention to complete a private placement (the “Private... Learn More
Edesa Biotech and Light chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders
April 20, 2020
TORONTO, ON / ACCESSWIRE / April 20, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, today announced a strategic agreement with Light Chain Bioscience (a brand of... Learn More
March 12, 2020
SUMMIT, N.J. (GLOBE NEWSWIRE) -- Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing an orally inhaled therapy designed to terminate an active epileptic... Learn More
Our investment team of 9 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.
Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.
“Lumira’s philanthropic vision of leveraging research, resources and knowledge to improve the lives of patients will strengthen St. Michael’s ability to accelerate the pace.”
Dr. Arthur Slutsky | Vice-President
Vice-President of Research at St. Michael’s Hospital
“Lumira’s model provides a new pathway for philanthropy to partner with investors in advancing healthcare innovation.”
Barbara Grantham | President & Ceo
VGH & UBC Hospital Foundation
“This distinctive approach to supporting innovation is very creative, very much needed and very much appreciated by Princess Margaret and University Health Network.”
Paul Alofs | President & Ceo
Princess Margaret Cancer Foundation
Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.
141 Adelaide Street
Canada, M5H 3L5
3, Place Ville Marie
Bureau 12350, Niveau L
Canada, H3B 0E7
1021 West Hastings Street,
Canada, V6E 0C3
303 Wyman Street